Scotiabank initiated coverage of Teva (TEVA) with an Outperform rating and $35 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva sees cash flow ‘probably around’ $2.7B in 2027
- Trump Weekly: White House postpones healthcare proposal after backlash
- Trump Trade: Trump says ‘tremendous progress’ on ending Ukrainian war
- JPMorgan views Medicare price cuts as inline with expectations
- Teva receives EC approvals for PONLIMSI, DEGEVMA